Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Highlights - November 2016


Skin sensitisation is one of the success stories in the effective transition from in vivo testing to an integrated in vitro testing approach. Mechanistically, the process underlying skin sensitization has been well characterized within an Adverse Outcome Pathway (AOP). This has led to a number of in vitro assays being developed to cover the Key Events within the AOP – these include the Direct Peptide Reactivity Assay (DPRA), KeratinoSens™ and the human Cell Line Activation Test (h-CLAT).

This month, Cyprotex announced the launch of its h-CLAT service, alongside its existing KeratinoSens™ and DPRA services. We are now one of the few companies which offer all three of the in vitro assays for supporting skin sensitization classification.

We have also co-published our research in the field of MEA and human iPSC-derived cardiomyocytes in the Toxicological Sciences journal, and co-presented a poster with Sciex on our combined analytical capabilities at the DMDG meeting.

Learn more about our new capabilities and research below.

Complete in vitro skin sensitisation package

Cyprotex have recently launched the human Cell Line Activation Test (h-CLAT), and can now offer all three in vitro assays which cover the Key Events within the skin sensitisation AOP.

Learn more

in silico prediction
New publication on the use of in vitro methods to detect human cardiotoxicity

A joint study, that brought together researchers from several organisations, examines the different in vitro approaches for understanding the cardiotoxicity of sofosbuvir when administered in combination with amiodarone. The study highlights the importance of MEA and human iPSC-derived cardiomyocytes in providing a valuable insight into the mechanism behind the adverse event.

Learn more

3D microtissue research
Improving efficiency in ADME screening

At the recent DMDG meeting in Paris, Cyprotex co-presented a poster with Sciex on the use of TripleTOF® instruments for improving the efficiency of ADME screening.

Download the poster
In vitro skin metabolism
Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.